- info@cohortias.com
- Sitio en Español
- Careers
- Network
COVID-19 resources / Clinical Research Insights and News
The Cohortias Blog
Stay informed
COVID-19 resources
Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.
Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.
Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.
Clinical Trials in Latin America | Cohortias the CRO of LATAM
Welcome to the realm of clinical trials in Latin America, a region pulsating with cultural diversity and a growing prominence in the global healthcare landscape. ...
Clinical Trials in Argentina | Leading CRO in LATAM – Cohortias
Step into the world of clinical trials in Argentina, a country known for its rich cultural heritage and growing prominence in the global research landscape. ...
Clinical Trials in Brazil | Leading CRO in LATAM – Cohortias
Step into the world of clinical trials in Brazil, a country renowned for its rich cultural heritage and rapidly growing presence in the global research ...
Clinical Trials in Colombia | Leading CRO in LATAM – Cohortias
Join us as we explore the vibrant landscape of clinical trials in Colombia, a country with a rapidly growing presence in the global research arena. ...
COVID-19 Research - Free Consultation
The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.
The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.
